Cabazitaxel: a new drug for metastatic prostate cancer.
作者信息
Bilusic Marijo, Dahut William L
机构信息
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Asian J Androl. 2011 Mar;13(2):185-6. doi: 10.1038/aja.2010.161. Epub 2010 Dec 13.
Abstract
摘要
相似文献
1
Cabazitaxel: a new drug for metastatic prostate cancer.卡巴他赛：一种用于转移性前列腺癌的新药。
Asian J Androl. 2011 Mar;13(2):185-6. doi: 10.1038/aja.2010.161. Epub 2010 Dec 13.
2
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.卡巴他赛：转移性去势抵抗性前列腺癌的新型二线治疗药物。
Drug Des Devel Ther. 2011 Mar 10;5:117-24. doi: 10.2147/DDDT.S13029.
3
Cabazitaxel for the treatment of castration-resistant prostate cancer.卡巴他赛治疗去势抵抗性前列腺癌。
Future Oncol. 2011 Jan;7(1):15-24. doi: 10.2217/fon.10.168.
4
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.多西他赛耐药转移性去势抵抗性前列腺癌的治疗选择：成本效益分析。
PLoS One. 2013 May 22;8(5):e64275. doi: 10.1371/journal.pone.0064275. Print 2013.
5
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.静脉治疗用于去势抵抗性前列腺癌：毒性和不良反应。
Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S15-9. doi: 10.1016/j.urolonc.2011.09.003. Epub 2011 Oct 19.
6
Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.专家意见：多西他赛治疗失败后去势抵抗性前列腺癌的化疗应用
Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16.
7
Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel.
Lancet Oncol. 2016 Jul;17(7):872-873. doi: 10.1016/S1470-2045(16)30165-6. Epub 2016 May 24.
8
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.多西他赛在 TAX 327 试验中用于转移性去势抵抗性前列腺癌（mCRPC）老年男性中的耐受性和疗效。
J Geriatr Oncol. 2014 Apr;5(2):119-26. doi: 10.1016/j.jgo.2013.12.001. Epub 2014 Jan 2.
9
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.卡巴他赛对 TROPIC 试验中转移性去势抵抗性前列腺癌男性患者的 2 年生存率和肿瘤相关疼痛缓解的影响。
Ann Oncol. 2013 Sep;24(9):2402-8. doi: 10.1093/annonc/mdt194. Epub 2013 May 30.
10
Cabazitaxel for prostate cancer: patient preparation and ongoing care.
Br J Nurs. 2012;21(9):S13-7. doi: 10.12968/bjon.2012.21.Sup6.S13.
引用本文的文献
1
The Efficacy of Cabazitaxel in Treating Prostate Cancer: A Systematic Review and Meta-Analysis.卡巴他赛治疗前列腺癌的疗效：系统评价和荟萃分析。
Am J Mens Health. 2024 Sep-Oct;18(5):15579883241285162. doi: 10.1177/15579883241285162.
本文引用的文献
1
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
2
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
3
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.MDV3100 在去势抵抗性前列腺癌中的抗肿瘤活性：一项 1-2 期研究。
Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.
4
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
5
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.一项针对紫杉烷耐药转移性乳腺癌患者的多中心II期研究，研究中每3周静脉输注1小时的XRP6258。
Ann Oncol. 2008 Sep;19(9):1547-52. doi: 10.1093/annonc/mdn171. Epub 2008 Apr 23.
6
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.基于多西他赛化疗的改善潜力：药理学综述。
Br J Cancer. 2005 Jul 25;93(2):173-7. doi: 10.1038/sj.bjc.6602698.
7
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.多西他赛与雌莫司汀对比米托蒽醌和泼尼松治疗晚期难治性前列腺癌的疗效
N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.
8
9
Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.以1小时或3小时输注方式给药的紫杉烷衍生物RPR 109881A在晚期实体瘤患者中的I期临床和药代动力学研究。
Ann Oncol. 2002 Jul;13(7):1140-50. doi: 10.1093/annonc/mdf174.
Zotero 插件